Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sagimet Biosciences Inc. - Series A Common Stock (NQ: SGMT )

3.510 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 185,132
Open 3.500
Bid (Size) 3.470 (1)
Ask (Size) 3.650 (1)
Prev. Close 3.510
Today's Range 3.490 - 3.590
52wk Range 2.390 - 7.380
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Sagimet Biosciences Reports Full Year 2024 Financial Results and Provides Corporate Updates
From Sagimet Biosciences Inc.
Via GlobeNewswire
Sagimet Biosciences Announces Clearance of IND for FASN Inhibitor TVB-3567, to be Developed for the Treatment of Acne
From Sagimet Biosciences Inc.
Via GlobeNewswire

Performance

YTD
-21.83%
-21.83%
1 Month
-23.19%
-23.19%
3 Month
-25.48%
-25.48%
6 Month
-6.65%
-6.65%
1 Year
-29.66%
-29.66%

More News

Read More
Sagimet Biosciences Announces Oral Presentation at the MASH Pathogenesis and Therapeutic Approaches Keystone Symposium
From Sagimet Biosciences Inc.
Via GlobeNewswire
This Vital Farms Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Via Benzinga
Sagimet Biosciences Announces Oral Presentation at the 9th Annual MASH-TAG 2025 Conference
From Sagimet Biosciences Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Why Edgewise Therapeutics Shares Are Trading Higher By Over 26%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Sagimet Biosciences to Participate in the Piper Sandler 36th Annual Healthcare Conference
From Sagimet Biosciences Inc.
Via GlobeNewswire
Sagimet Biosciences Presents Clinical Denifanstat and Preclinical FASN Inhibitor Data at AASLD - The Liver Meeting® 2024
From Sagimet Biosciences Inc.
Via GlobeNewswire
Sagimet Biosciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
From Sagimet Biosciences Inc.
Via GlobeNewswire
This Nvidia Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Via Benzinga
Sagimet Biosciences to Participate in the UBS Global Healthcare Conference
From Sagimet Biosciences Inc.
Via GlobeNewswire
Madrigal Catapults After Novo's Wegovy Proves It's No 'Silver Bullet' In MASH
Via Investor's Business Daily
Sagimet Biosciences Announces Successful Completion of End-of-Phase 2 Interactions with FDA on the Development of Denifanstat for MASH; Phase 3 Program Initiation Expected by End of 2024
From Sagimet Biosciences Inc.
Via GlobeNewswire
Sagimet Biosciences Announces Upcoming Presentations at AASLD - The Liver Meeting® 2024
From Sagimet Biosciences Inc.
Via GlobeNewswire
Sagimet Biosciences Announces Publication of Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 MASH in The Lancet Gastroenterology & Hepatology
From Sagimet Biosciences Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Sagimet Receives FDA Breakthrough Therapy Designation for Denifanstat in MASH
From Sagimet Biosciences Inc.
Via GlobeNewswire
Sagimet Biosciences to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference and Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Sagimet Biosciences Inc.
Via GlobeNewswire
Sagimet Announces Oral Presentation at the 8th Annual MASH Drug Development Summit
From Sagimet Biosciences Inc.
Via GlobeNewswire
Sagimet Biosciences to Participate in Two Upcoming Investor Conferences
From Sagimet Biosciences Inc.
Via GlobeNewswire
SGMT Stock Earnings: Sagimet Biosciences Beats EPS for Q2 2024
Via InvestorPlace
Sagimet Biosciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
From Sagimet Biosciences Inc.
Via GlobeNewswire
Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Directors
From Sagimet Biosciences Inc.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.